Innovative Tools for Molecular and Cell Biology

Innovative Tools for Molecular and Cell Biology


TransIT®-LT1 Transfection Reagent

A broad spectrum & low toxicity DNA transfection reagent


  • Comparable performance to FuGENE® 6 Reagent, but at lower cost.
  • Broad Spectrum DNA Delivery — Utilize one transfection reagent and protocol for a variety of cells.
  • Low Cellular Toxicity — Maintain cell density and reduce experimental biases.
  • High Efficiency Delivery — Achieve expression in a large population of cells for experimental success.
  • Deliver Single or Multiple Plasmids — Suitable for many applications such as gene expression, siRNA/shRNA expression, viral production and promoter analysis.
  • Free samples available


  • TransIT®-LT (low toxicity) Transfection Reagents offer clear advantages for intracellular delivery of DNA via transfection, including ease of use, transfection reproducibility, and state-of-the-art transfection efficiencies with significantly reduced levels of cell damage. In addition, transfections with TransIT®-LT1 do not require media changes and can be carried out in serum-containing media. This unique combination of features makes these transfection reagents ideal for all gene expression studies where the post-transfection state of the cell is important.

The TransIT®-LT1 Reagent Efficiently Delivers DNA to a Variety of Cell Lines.

The TransIT®-LT1 Reagent Efficiently Delivers DNA to a Variety of Cell Lines

The TransIT®-LT1 Reagent Efficiently Delivers DNA to a Wide Variety of Cell Lines. Using the TransIT®-LT1 Transfection Reagent, cells were transfected with the pEGFP-C1 expression vector, and the percentage of EGFP expressing cells was determined 24-48 hours post-transfection.

The TransIT®-LT1 Reagent Exhibits Low Cellular Toxicity Compared to Another Transfection Reagent.

Nontransfected TransIT®-LT1 Reagent Competitor Reagent L
a) Nontransfectedb) TransIT®-LT1 Reagentc) Competitor Reagent L

The TransIT®-LT1 Reagent Exhibits Low Cellular Toxicity Compared to Another Leading Transfection Reagent. COS-7 cells were transfected using Mirus Bio’s TransIT®-LT1 Reagent or a leading competitor, Reagent L, according to the manufacturer’s recommendations. The presence of rounded cells and the disappearance of many cells in the Reagent L transfected sample, compared to the nontransfected cells (a), illustrates the extreme cellular toxicity observed with Reagent L (c). In contrast, the cells transfected with the TransIT®-LT1 Reagent (b) exhibited minimal cellular toxicity.

The TransIT®-LT1 Reagent Performs Best in the Presence of Serum Containing Media.

Comparison of TransIT®-LT1 transfection efficiency in various cell types and different media

The TransIT®-LT1 Reagent Performs Best in the Presence of Serum Containing Media. Using the TransIT®-LT1 Reagent, the indicated cells lines were transfected with a luciferase expression vector using three different media conditions: cells were transfected in the presence of (1) serum-free media or (2) complete media with media changes 4 hours post-transfection, or transfected in the presence of (3) complete media with no media change post-transfection. The cells were harvested 48 hours post-transfection, and the total luciferase activity per well was determined.


  • For shipping and storage information please click on Order#.
Order# Description Amount Price Data Sheet
MIR2304 TransIT®-LT1 Transfection Reagent 0.4 ml 204,00 PDF
MIR2300 TransIT®-LT1 Transfection Reagent 1 ml 323,00 PDF
MIR2305 TransIT®-LT1 Transfection Reagent 5 x 1 ml 1399,00 PDF
MIR2306 TransIT®-LT1 Transfection Reagent 10 x 1 ml 2586,00 PDF
MIR2310 TransIT®-LT1 Transfection Reagent 0.1 ml 0,00 PDF
  • All prices are in EURO excl. VAT and shipping. Only available in selected countries.

  • * Sample Policy:
    MoBiTec together with Mirus considers sample requests for up to three different transfection products and one electroporation product per laboratory. Please include all samples to be tested in a single request.


  • TransIT®-LT1 Cell Transfection Protocol (PDF)
  • TransIT®-LT1 FAQ (PDF)
  • TransIT®-LT1 MSDS (PDF)


(cell type in bold)

  1. Cohen EE, Lingen MW, Zhu B, Zhu H, Straza MW, Pierce C, Martin LE, Rosner MR.   2006.  Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.  Cancer Res..  66(12):6296-303.   293T Pubmed
  2. Kenneth Dakin A1 and Wen-Hong Li A1  2006.  Local Ca2+ Rise Near Store Operated Ca2+ Channels Inhibits Cell Coupling During Capacitative Ca2+ Influx   Cell Communication & Adhesion .  13:(1-2) 29 .   HeLa Pubmed
  3. Chuang, Chang, Chang, Yao, Chen.   2006.  Histone deacetylase 3 binds to and regulates the GCMa transcription factor.   Nucleic Acids Research .  34(5): 1459. BeWo, JEG-3, JAR, 293T Pubmed
  4. Small-Howard A, Morozova N, Stoytcheva Z, Forry EP, Mansell JB, Harney JW, Carlson BA, Xu XM, Hatfield DL, Berry MJ.  2006.  Supramolecular complexes mediate selenocysteine incorporation in vivo.   Mol Cell Biol..  (6):2337.   293 Pubmed
  5. Li, Deng, Nail, Bailey, Kraus, Ruppert,Lobo-Ruppert.   2006.  Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation.  Oncogene .  25: 609. 293 Pubmed
  6. Ada-Nguema, Xenias, Sheetz, and Keely.  2006.  The small GTPase R-Ras regulates organization of actin and drives membrane protrusions through the activity of PLC  J. Cell Sci.  119: 1307 - 1319. COS , MCF10A Pubmed
  7. Qiao, Shapiro, Fosbrink, Rus, Kumar, Passaniti.  2006.  Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation.  Journal of Biological Chemistry.  281: 7118.   293T, Human Bone Marrow EC Line (HBME) Pubmed
  8. Hartman, Dover, Towner, and Nichol.  2006.  Reverse Genetic Generation of Recombinant Zaire Ebola Viruses Containing Disrupted IRF-3 Inhibitory Domains Results in Attenuated Virus Growth In Vitro and Higher Levels of IRF-3 Activation without Inhibiting Viral Transcription or Replication.  J. Virol.  80:6430 - 6440 293T, Vero Pubmed
  9. Rachlin and Otey.  2006.  Identification of palladin isoforms and characterization of an isoform-specific interaction between Lasp-1 and palladin.  J. Cell Sci.  119: 995 - 1004.   HeLa Pubmed
  10. Kiyotaka Machida, Yoshihiro Ohta, and Hiroyuki Osada  2006.  Suppression of Apoptosis by Cyclophilin D via Stabilization of Hexokinase II Mitochondrial Binding in Cancer Cells   J. Biol. Chem..  281:14314.   HeLa Pubmed
  11. more literature